The present invention relates generally to antigen-specific tolerogenic protein therapy and its use to treat adverse immune responses, such as those associated with autoimmune diseases such as multiple sclerosis (MS) and hemophilia. In particular, the present invention includes the application of B cell targeted IgG fusion proteins as antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies. The fusion protein comprises a B cell specific targeting module, a constant region of human IgG4 heavy chain or fragment thereof, and an antigen. [Selection] Figure 2B本発明は一般に、抗原特異的寛容原性タンパク質療法ならびに多発性硬化症(MS)および血友病などの自己免疫疾患と関連するものなどの、有害な免疫応答を処置するためのその使用に関する。特に、本発明は、単独での、または阻害抗体と組み合わせた、抗原特異的寛容原性タンパク質療法としてのB細胞標的化IgG融合タンパク質の適用を含む。融合タンパク質は、B細胞特異的標的化モジュール、ヒトIgG4重鎖の定常領域またはその断片、および抗原を含む。【選択図】 図２Ｂ
